Suppr超能文献

现场记录:2015 年肯塔基州新生儿和成人重症监护病房中的携带 Verona 整合子编码的金属β-内酰胺酶的耐碳青霉烯类肠杆菌科细菌。

Notes from the Field: Verona Integron-Encoded Metallo-Beta-Lactamase-Producing Carbapenem-Resistant Enterobacteriaceae in a Neonatal and Adult Intensive Care Unit--Kentucky, 2015.

出版信息

MMWR Morb Mortal Wkly Rep. 2016 Feb 26;65(7):190. doi: 10.15585/mmwr.mm6507a5.

Abstract

During August 4-September 1, 2015, eight cases of Verona integron-encoded metallo-beta-lactamase (VIM)-producing Carbapenem-resistant Enterobacteriaceae (CRE) colonization were identified in six patients, using weekly active surveillance perirectal cultures in a Kentucky tertiary care hospital. No cases of clinical infection or complications attributable to colonization were reported. Four of the eight isolates were identified as Enterobacter cloacae; other organisms included Raoultella species (one), Escherichia coli (one), and Klebsiella pneumoniae (two). Six isolates were reported in a neonatal intensive care unit (ICU), and two isolates in an adult trauma and surgical ICU. Patient ages at isolate culture date ranged from 21 days to 68 years. Fifty percent of the patients were male. Previously, only one VIM-producing CRE-colonized patient (an adult, in 2013) had been reported by the same hospital. The six cases are the largest occurrence of VIM-producing CRE colonization reported in the United States and the only recognized cluster of VIM-producing CRE colonization in the United States reported to include a neonatal population. Despite environmental sampling over the same period, surveying patients for exposure to health care outside the United States, surveying health care providers for risk factors, and surveillance culturing of health care provider nares and axillae, a source of VIM-producing CRE has not been identified for this cluster. Prevention measures throughout the ICUs have been enhanced in response to this cluster, as detailed in CDC's 2015 CRE toolkit update.

摘要

2015 年 8 月 4 日至 9 月 1 日期间,肯塔基州一家三级保健医院每周对直肠周围进行主动监测培养,共发现 6 名患者有 8 例 Verona 整合子编码金属β-内酰胺酶(VIM)产碳青霉烯类耐药肠杆菌科(CRE)定植。没有报告因定植而发生临床感染或并发症的病例。8 株分离株中有 4 株为阴沟肠杆菌;其他病原体包括罗尔斯顿菌(1 株)、大肠埃希菌(1 株)和肺炎克雷伯菌(2 株)。6 株分离株来自新生儿重症监护病房(NICU),2 株来自成人创伤和外科重症监护病房(SICU)。分离株培养日期患者年龄从 21 天到 68 岁不等。50%的患者为男性。此前,同一医院仅报告过 1 例 VIM 产 CRE 定植患者(1 例成人患者,2013 年)。这 6 例是美国报告的 VIM 产 CRE 定植中最大的一次,也是美国唯一被确认的 VIM 产 CRE 定植聚集事件,包括新生儿人群。尽管在此期间进行了环境采样,对患者进行了在美国以外的医疗保健机构暴露调查,对医疗保健提供者进行了危险因素调查,以及对医疗保健提供者鼻腔和腋窝进行了监测培养,但仍未确定该聚集事件的 VIM 产 CRE 来源。作为 CDC 2015 年 CRE 工具包更新的一部分,针对这一聚集事件,已在各重症监护病房加强了预防措施。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验